Medical Communications

The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has approved a new indication for MSD’s Ezetrol (ezetimibe), making it …

NHS England has approved proposed reforms of the Cancer Drugs Fund, following the end of the 12-week consultation period earlier …

Gilead Sciences has reported 48-week Phase III trial results suggesting fixed-dose Emtriva and tenofovir alafenamide (F/TAF) combinations matched its Truvada …

The US Senate has confirmed Dr Robert Califf as Commissioner of the Food and Drugs Administration, in an overwhelming 89-4 …

Valeant says it is likely to restate its financial results for the last two years, in the wake of the …

ViiV Healthcare has completed its previously-announced acquisition of Bristol-Myers Squibb’s late-stage HIV R&D assets and its portfolio of preclinical and …

Dr Robert Califf, President Obama’s nominee to head up the US Food and Drugs Administration as commissioner, has edged a …

The March 2016 edition of Pharmafocus is now live and available to read here.

Romosozumab development partners Amgen and UCB have announced positive top-line results from a Phase III study of the drug in postmenopausal …

Germany’s Merck has extended its infertility programme ‘Merck More than a Mother’ to Uganda, launching the campaign in a second …

Novartis’ PKC412 (midostaurin)  has become the latest in a sequence of FDA Breakthrough Therapy designations awarded this week- bagging the …

NICE says it needs additional trial data before it can recommend Alexion’s enzyme replacement therapy Kanuma (sebelipase alfa) for the …

A trial of more than 1,500 GP practices has shown that sending general practitioners (GPs) letters giving feedback on their …

It began with a promise to UK voters to end ‘benefit tourism’ and to negotiate more flexibility in the UK’s …

Bristol Myers-Squibb’s Opdivo (nivolumab) will be available through the Early Access to Medicines  Scheme (EAMS) as a monotherapy to UK …